A revolutionary, needle-free technology that has been designed to deliver retina therapies non-invasively, to the back of the eye, has been launched.

The incidence of endophthalmitis following injections of anti-VEGF drugs is lower when the injections are given in an office setting than the rates reported from clinical trials, which require a more extensive pre-injection regimen.

A protein, called Robo4, has been identified which appears to play an important role in the development of stable, working blood vessels.

Preliminary results of a study using the NSAID Xibrom (bromfenac ophthalmic solution 0.09%; ISTA Pharmaceuticals) therapy in combination with Lucentis (ranibizumab; Novartis) in patients with wet age-related macular degeneration (AMD), suggests that it may result in fewer injections being required.

The side effects and complications associated with intravitreal bevacizumab (Avastin) are minimal and can be prevented, in most cases, by careful injection and good patient selection.

A single intravitreal injection of the fusion protein KH902 can effectively inhibit leakage and growth of choroidal neovascularization in rhesus monkeys.

Genentech has resolved its dispute with American ophthalmologists over the off-label use of its anti-VEGF drug Avastin, and will now allow physicians to purchase the drug directly from authorized wholesale distributors.

Triple therapy for age-related macular degeneration (AMD) can stabilize vision and reduce the re-treatment rate in patients who do not respond to initial anti-VEGF therapy.

Judah Folkman, MD, the pioneer of angiogenesis research, died on January 15th 2008.